Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 3Gastrointestinal 1CNS 1

Conditions

Small Cell Lung Carcinoma 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 19Radiosurgery 16Radiotherapy 14Specimen Handling 11Pemetrexed 8Paclitaxel 6Erlotinib Hydrochloride 6Docetaxel 6Carboplatin 6Bevacizumab 5pembrolizumab 4Temozolomide 4Spinal Puncture 4Cisplatin 4osimertinib 3Taxes 3Nivolumab 3Gemcitabine 3Gefitinib 3Filgrastim 3Drug Therapy 3trametinib 2selpercatinib 2sapanisertib 2motexafin gadolinium 2epothilone B 2dabrafenib 2X-Rays 2Vorinostat 2Trastuzumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lung Neoplasms × berzosertib × CNS × Clear all
NCT02589522 2026-04-29

Testing the Safety of M6620 (VX-970) When Given With Standard Whole Brain Radiation Therapy for the Treatment of Brain Metastases From Non-small Cell Lung Cancer, Small Cell Lung Cancer, or Neuroendocrine Tumors

National Cancer Institute (NCI)

Phase 1 Active not recruiting
15 enrolled 10 charts
CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡